Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats
Abstract Background Roxadustat is a novel hypoxia- inducible factor-prolyl hydroxylase inhibitor(HIF-PHI) used to treat anemia in chronic kidney disease (CKD) patients. It has been reported that roxadustat can slow down kidney damage and delay the development of kidney fibrosis. Anemia and iron defi...
Saved in:
| Main Authors: | Zhaoli Gao, Yanxia Gao, Qiang Wang, Qi Wang, Peng Lu, Hailin Lv, Haoran Xue, Xiaotian Ma, Shuen Li, Zhao Hu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-04045-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01) -
A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01) -
Progress of HIF-1α and HIF-PHI in vascular calcification of chronic kidney disease
by: WANG Ao, et al.
Published: (2024-08-01) -
Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01) -
History,current status and treatment advances of iron overload in anemia of chronic kidney disease
by: Xing Jie, et al.
Published: (2022-05-01)